Avinger, Inc. Common Stock

AVGR

Market cap $1.52M

SANTA CLARA, CALIFORNIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- On February 10, 2025, Avinger, Inc., a Delaware Corporation (“Avinger” or the “Company”), entered into a general assignment for the benefit of creditors (the “Assignment”) in favor of Avinger (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”).

Avinger, Inc. (NASDAQ:AVGR ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the Avinger Third Quarter 2024 Results Conference Call.

Avinger (AVGR) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.03. This compares to loss of $2.92 per share a year ago.

Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024. Third Quarter and Recent Highlights Reported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.

REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.

REDWOOD CITY, CA / ACCESSWIRE / September 18, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of a new U.S. patent and the allowance of five additional U.S. patents that are expected to issue over the next four months. These patents expand intellectual property protection for Avinger's proprietary image-guided system and devices for both peripheral and coronary applications.

Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.

REDWOOD CITY, CA / ACCESSWIRE / August 20, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of the Pantheris LV image-guided directional atherectomy system. With the initiation of full commercial launch, all current and prospective accounts can now order the Pantheris LV device, a line extension of the first and only image-guided atherectomy device for the treatment of peripheral artery disease (PAD).

Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript